tirzepatide stock ECO 2026: shows potential for T1D treatment Eli Lilly Adds Highest Doses
Description
The Bottom Line GLP1 therapies are changing the game for T2D, and their influence is continuing to spread across the broader chronic disease landscape
Arm hurts after Ozempic injection
Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall
The controversial ad also hit a nerve with the pharma industry and lawmakers, who lashed the company for "deceptive" advertising.
